Bayer AktiengesellschaftBAYRY
Oncology40 cited findings · profile updated 2026-08-20
About Bayer Aktiengesellschaft
BAYRY is an oncology research site. The company's drug Nexavar has a NOEC for Daphnia sp. Reproduction Test of 0.860 µg/L. In trial 14387, treatment with Stivarga was associated with various adverse events. These included Potassium decreased (All Grades) at 25.7% and 8.3%, Bilirubin increased (All Grades) at 17.1% and 44.6%, and Phosphate decreased (All Grades) at 57.4% and 11.1%. Grade 3 adverse events in trial 14387 included Phosphate decreased at 30.5% and 3.6%, Bilirubin increased at 5.2% and 9.6%, and Lymphocyte count decreased at 9.3% and 3.2%. Grade 4 adverse events in trial 14387 included Bilirubin increased at 2.6% and Phosphate decreased at 0.6%.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| NOEC for Daphnia sp. Reproduction Test | 0.860 µg/L | Bayer Aktiengesellschaft — Nexavar EMA EPAR variation assessment repor, p.p.11 |
| Potassium decreased (All Grades) | 25.7 % | Bayer Aktiengesellschaft — Stivarga EMA EPAR public assessment report, p.p.72 |
| Phosphate decreased (Grade 3) | 30.5 % | Bayer Aktiengesellschaft — Stivarga EMA EPAR public assessment report, p.p.72 |
| Bilirubin increased (All Grades) | 44.6 % | Bayer Aktiengesellschaft — Stivarga EMA EPAR public assessment report, p.p.72 |
| Lymphocyte count decreased (All Grades) | 54.1 % | Bayer Aktiengesellschaft — Stivarga EMA EPAR public assessment report, p.p.72 |
| Calcium decreased (All Grades) | 59.3 % | Bayer Aktiengesellschaft — Stivarga EMA EPAR public assessment report, p.p.72 |
Key projects
- Nexavar
NOEC for Daphnia sp. Reproduction Test was 0.860 µg/L.
- Stivarga (Trial 14387)
Potassium decreased (All Grades) was observed in 25.7% of patients.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →